BioSpace

Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder

Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.

By BioSpace

1 min read
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights